FDA NSAID Panel Nixes Naproxen Heart Safety Claim
(MedPage Today) -- In 16-9 vote, the FDA advisory committee assessing NSAID safety said the warning label on naproxen should not be changed to suggest it has a better cardiovascular risk profile than other drugs in this class. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - February 12, 2014 Category: Psychiatry Source Type: news
National Briefing | Health: Panel Won’t Change Naproxen Labels
A panel convened by the Food and Drug Administration concluded that naproxen, the active ingredient in Aleve, did not pose a lower risk of cardiovascular problems than ibuprofen and similar pain drugs. (Source: NYT)
Source: NYT - February 12, 2014 Category: American Health Authors: By SABRINA TAVERNISE Tags: Drugs (Pharmaceuticals) Food and Drug Administration Labeling and Labels Lancet, The (Journal) Source Type: news
FDA Advisers: Meta-Analysis Does Not Prove That Naproxen Carries Lower CV Risk (FREE)
By Amy Orciari Herman
Data from a meta-analysis suggesting that naproxen carries lower cardiovascular risk than other nonsteroidal anti-inflammatory drugs are not reliable, FDA advisers concluded on Tuesday. … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 12, 2014 Category: Primary Care Source Type: news
FDA Advisory Panel Votes Down CV Safety Claim for Naproxen FDA Advisory Panel Votes Down CV Safety Claim for Naproxen
With a 16-9 vote, the FDA's AAC and DSARM panel members said the evidence is insufficient to suggest naproxen has a lower cardiovascular risk profile than other NSAIDs. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 11, 2014 Category: Cardiology Tags: Cardiology News Alert Source Type: news
FDA Scientist Lays Out Case on Naproxen
An epidemiologist with the Food and Drug Administration on Monday laid out why the anti-inflammatory pain drug naproxen may carry lower cardiovascular risks than comparable drugs. (Source: WSJ.com: Health)
Source: WSJ.com: Health - February 10, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news
FDA Advisers Revisit Heart Risks Posed by Painkillers
Studies suggest naproxen (Aleve) may pose less of a threatSource: HealthDay
Related MedlinePlus Page: Pain Relievers (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 10, 2014 Category: Consumer Health News Source Type: news
FDA Panel to Weigh Painkillers' Cardiac Risk
An FDA panel could soon direct the fate of billions of dollars in household-name pain drugs like Advil and Aleve over the question of which ones pose greater cardiac risk. (Source: WSJ.com: Health)
Source: WSJ.com: Health - February 10, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news
Ibuprofen, Aleve Won't Raise Miscarriage Risk
However, NSAIDs should not be taken in third trimester of pregnancy, authors advise
Source: HealthDay
Related MedlinePlus Pages: Miscarriage, Pain Relievers, Pregnancy and Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 3, 2014 Category: Consumer Health News Source Type: news
FDA Considers Loosening Naproxen's CV WarningFDA Considers Loosening Naproxen's CV Warning
The FDA says the data "suggest that naproxen is not associated with an increased risk of cardiovascular thrombotic events" and recommends changing the label to reflect this lower risk. Heartwire (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 29, 2014 Category: Drugs & Pharmacology Tags: Cardiology News Source Type: news
Bayer's Aleve May Have Lower Cardiac Risk Than Rival Painkillers
The FDA said a review of popular painkillers found naproxen, sold by Bayer under the brand name Aleve, may carry a lower cardiac risk than rival drugs. (Source: WSJ.com: Health)
Source: WSJ.com: Health - January 29, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news
Pro ArthMax by Human Science Foundation: Recall - Undeclared Drug Ingredients
Undeclared Chlorzoxazone, Nefopam, Diclofenac, Ibuprofen, Naproxen, and Indomethacin. Pro ArthMax has a reasonable probability of resulting in fatal adverse events. (Source: FDA MedWatch)
Source: FDA MedWatch - January 14, 2014 Category: American Health Source Type: news
Remission Comes Sooner With Early Tx for SpA (CME/CE)
(MedPage Today) -- Early treatment of active axial spondyloarthritis (SpA) with naproxen plus infliximab (Remicade) led to high rates of remission, which then were sustained whether patients continued to receive naproxen or not after stopping the infliximab, an international research group reported in two studies. (Source: MedPage Today Pain Management)
Source: MedPage Today Pain Management - November 22, 2013 Category: Anesthesiology Source Type: news
